A 2021 update: Approach to asthma management in adults

N. Schellack*, A. Truter, P. N. Ntuli, N. Mokwele, K. Mogale, A. Esterhuizen

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Asthma is a chronic inflammatory disease that causes hyper-responsiveness of the bronchial tree, with reversible airflow obstruction. The condition places a significant burden on our healthcare system. Chronic asthma can cause remodelling of the airway. Patients suffering from asthma should be aware of the signs and symptoms thereof, as well as the factors that can precipitate an asthmatic attack. Asthma is mostly classified as either acute or chronic; the diagnosis of asthma is based on identifying both a characteristic pattern of respiratory symptoms and variable expiratory airflow limitation. Treatment is based on how the patient presents and includes bronchodilators, inhaled corticosteroids and mast cell stabilisers. This article provides an overview of the diagnosis, characterisation and treatment of asthma.

Original languageEnglish
Pages (from-to)17-24
Number of pages8
JournalSA Pharmaceutical Journal
Volume88
Issue number4
Publication statusPublished - 31 Aug 2021

Keywords

  • Asthma
  • Bronchodilator
  • Inhaled corticosteroid
  • LABA
  • Peak expiratory flow
  • SABA
  • Spirometry
  • β-agonist

Fingerprint

Dive into the research topics of 'A 2021 update: Approach to asthma management in adults'. Together they form a unique fingerprint.

Cite this